Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback